You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
|
|---|---|
| Published in |
BMC Cancer, July 2015
|
| DOI | 10.1186/s12885-015-1444-1 |
| Pubmed ID | |
| Authors |
Aleksandra Butrym, Ewa Lech-Maranda, Elżbieta Patkowska, Beata Kumiega, Maria Bieniaszewska, Andrzej Mital, Krzysztof Madry, Tigran Torosian, Ryszard Wichary, Justyna Rybka, Krzysztof Warzocha, Grzegorz Mazur |
| Abstract |
Lenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk MDS with isolated del5q treated with lenalidomide, outside the clinical trials. 36 red blood cell (RBC) transfusion-dependent patients have been included in the study. Patients received lenalidomide 10 mg/day on days 1-21 of 28-day cycles. 91.7 % of patients responded to lenalidomide treatment: 72.2 % achieved erythroid response, 19.4 % achieved minor erythroid response and 8.4 % of patients did not respond to treatment. Response depended on number of previous treatment lines (p = 0.0101), International Prognostic System Score (IPSS; p = 0.0067) and RBC transfusion frequency (p = 0.0139). Median duration of response was 16 months (range 6-60 months). Treatment was well tolerated. We observed hematological toxicity (grade 3 and 4): neutropenia in 16 (44.4 %) patients and thrombocytopenia in 9 (25 %) patients. Two patients (5.5 %) progressed to high-risk MDS and two subsequent progressed to acute myeloid leukemia. A Kaplan-Meier estimate for overall survival at 5 years in the study group was 79.0 ± 8.8 %. Lenalidomide in this group of patients was beneficial for the treatment of RBC transfusion-dependency with well-known safety profile. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 6% |
| Unknown | 15 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Lecturer > Senior Lecturer | 2 | 13% |
| Other | 2 | 13% |
| Student > Doctoral Student | 2 | 13% |
| Student > Bachelor | 2 | 13% |
| Student > Master | 2 | 13% |
| Other | 3 | 19% |
| Unknown | 3 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 31% |
| Environmental Science | 1 | 6% |
| Computer Science | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Sports and Recreations | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 6 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2015.
All research outputs
#18,418,694
of 22,816,807 outputs
Outputs from BMC Cancer
#5,423
of 8,300 outputs
Outputs of similar age
#188,657
of 262,367 outputs
Outputs of similar age from BMC Cancer
#135
of 153 outputs
Altmetric has tracked 22,816,807 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,300 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,367 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.